• Circassia Ltd., of Oxford, UK, started a pivotal, large-scale Phase III study of its ToleroMune cat allergy treatment for rhinoconjunctivitis. The study will test safety and efficacy of the ToleroMune treatment in approximately 1,200 subjects from the U.S., Canada and Europe.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST